H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on IntelGenx Technologies (IGXT) today and set a price target of $1. The company’s shares closed on Friday at $0.41, close to its 52-week low of $0.39.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -11.9% and a 28.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Gritstone Oncology Inc, Trillium Therapeutics, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IntelGenx Technologies with a $1.25 average price target, a 206.1% upside from current levels. In a report issued on August 9, Maxim Group also maintained a Buy rating on the stock with a $1.50 price target.
See today’s analyst top recommended stocks >>
Based on IntelGenx Technologies’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.6 million. In comparison, last year the company had a GAAP net loss of $2.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast.
